Skip to main content

In re Hemispherx Biopharma, Inc. Litigation, 09-CV-5262-PD (E.D. Pa.)

Case Conclusion Date: 02.14.2011

Practice Area: Securities & Investment Fraud

Outcome: $3.6 million settlement achieved after defeating defendants' motion to dismiss Rule 10b-5 claims.

Description: Federal securities fraud class action against pharmaceutical company alleging that defendants knowingly made false statements about the company's new drug application for Ampligen (an experimental drug to treat chronic fatigue syndrome).

See all Legal Cases